I. Giunzioni

发表

Loss of Macrophage Low-Density Lipoprotein Receptor–Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor-&agr; Inhibition

M. Linton, L. Ding, S. Fazio, 2016, Arteriosclerosis, thrombosis, and vascular biology.

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.

Deanna L. Plubell, Rachel M. Devay, I. Predazzi, 2016, Cardiovascular research.

Local effects of human PCSK9 on the atherosclerotic lesion

Rachel M. Devay, I. Predazzi, M. Linton, 2016, The Journal of pathology.

Vascular Health and Risk Management Dovepress New Developments in Atherosclerosis: Clinical Potential of Pcsk9 Inhibition

H. Tavori, I. Giunzioni, 2022 .

PCSK9 Association With Lipoprotein(a).

Deanna L. Plubell, J. Minnier, S. Tsimikas, 2016, Circulation research.

Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms

M. Linton, S. Fazio, S. Rashid, 2014, Circulation.

PCSK 9 Association With Lipoprotein ( a )

Deanna L. Plubell, J. Minnier, S. Tsimikas, 2016 .

Response to letter regarding article, "Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms".

M. Linton, S. Fazio, S. Rashid, 2015, Circulation.

Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages

M. Linton, S. Fazio, J. Stafford, 2018, Circulation.

Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis

M. Linton, S. Fazio, H. Tavori, 2013, Circulation research.

PCSK9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein-B Lipoproteins Through Both LDL-Receptor Dependent and Independent Mechanisms Running title: Rashid et al.; PCSK9 Promotes Intestinal ApoB Overproduction

M. Linton, S. Fazio, S. Rashid, 2014 .

PCSK 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein-B Lipoproteins Through Both LDL-Receptor Dependent and Independent Mechanisms Running title :

M. Linton, S. Fazio, S. Rashid, 2014 .

Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL[S]

M. Linton, P. Yancey, S. Fazio, 2015, Journal of Lipid Research.

Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice[S]

M. Linton, A. Fogo, S. Fazio, 2014, Journal of Lipid Research.

PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9

S. Fazio, H. Tavori, I. Giunzioni, 2015, Current opinion in endocrinology, diabetes, and obesity.

Response by Mueller et al to Letter Regarding Article, "Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages".

M. Linton, S. Fazio, J. Stafford, 2019, Circulation.

Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis

M. Linton, S. Fazio, H. Tavori, 2013, Circulation research.

Response to Duell et al.

M. Linton, S. Fazio, H. Tavori, 2014, Circulation research.